Martins Mário R, Santos Rogério L D, Jatahy Kleber D N, Matta Marina C D, Batista Thales P, Júnior José Iran C, Begnami Maria D F S, Torres Leuridan C
Oncology Surgical Department, Sociedade Pernambucana de Combate ao Câncer-Hospital do Cancer de Pernambuco (SPCC-HCP), Recife, Brazil.
Translational Research Laboratory Prof. C. A. Hart, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil.
J Surg Oncol. 2018 Apr;117(5):840-844. doi: 10.1002/jso.25001. Epub 2018 Mar 12.
OX40, a membrane-bound molecule of the tumor-necrosis-factor-receptor superfamily, is a critical costimulatory receptor during the immune response, especially to T cells, but studies described their presence of OX-40 on neutrophils and monocytes, suggesting a potential role in the activation of immune response. Our aim was to characterize costimulatory receptors OX40 expression on circulating leukocytes in gastric cancer to identify novel targets for immunotherapy.
Peripheral blood mononuclear cells were isolated from 24 gastric cancer patients and 34 healthy controls and the expression of costimulatory (OX40) receptors were analyzed on T cells, neutrophil and monocyte using monoclonal antibodies by flow cytometry.
We found that the higher levels of OX40 + T cells, monocytes/OX40+ and neutrophils/OX40+ from gastric cancer patients when compared to controls (P < 0.0001), and also higher levels of OX40+ T cells when compared to stages III and IV (P = 0.02). Percentage levels of total T cells were similar between patients and controls.
OX40 as a therapeutic agent has been investigated in many preclinical tumor models. Our findings suggest that of levels of costimulatory in T cells in GC will direct future studies on the role that costimulatory receptors play in the failure of T cell-mediated immunity.
OX40是肿瘤坏死因子受体超家族的一种膜结合分子,是免疫反应尤其是对T细胞的关键共刺激受体,但有研究描述了中性粒细胞和单核细胞上存在OX-40,提示其在免疫反应激活中可能发挥作用。我们的目的是表征胃癌循环白细胞上共刺激受体OX40的表达,以确定免疫治疗的新靶点。
从24例胃癌患者和34例健康对照中分离外周血单个核细胞,使用单克隆抗体通过流式细胞术分析T细胞、中性粒细胞和单核细胞上共刺激(OX40)受体的表达。
我们发现,与对照组相比,胃癌患者的OX40+T细胞、单核细胞/OX40+和中性粒细胞/OX40+水平更高(P<0.0001),与III期和IV期相比,OX40+T细胞水平也更高(P = 0.02)。患者和对照组之间总T细胞的百分比水平相似。
OX40作为一种治疗剂已在许多临床前肿瘤模型中进行了研究。我们的研究结果表明,胃癌中T细胞共刺激水平将指导未来关于共刺激受体在T细胞介导的免疫失败中所起作用的研究。